首页 > 最新文献

Journal of Endovascular Therapy最新文献

英文 中文
Endovascular Conversion of a Failed Nellix AAA-Repair by a Custom-Made Branched Device. 用定制分支器械对失败的 Nellix AAA 进行血管内转换修复。
IF 1.5 2区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2026-04-01 Epub Date: 2024-08-27 DOI: 10.1177/15266028241276961
Baban Assaf, Martin J Austermann, Marco V Usai

Purpose: This technical note presents a case of a patient with a failed Nellix device (Endologix, Irvine, Calif) who was not deemed fit for open conversion. Our planned approach for repair involved an endovascular procedure utilizing a custom-made branched device.

Technique: An endovascular repair was performed via a custom-made four outer branched device in conjunction with a custom-made bifurcated graft featuring inverted limbs (Cook Inc., Bloomington, Ind). All branches were connected to the target vessel with Gore Viabahn VBX balloon-expandable covered stents (Gore & Associates Inc.).

Conclusion: Endovascular conversion with branched endovascular repair in a patient not deemed fit for open surgery was successfully performed, thereby reducing the risk of a high morbid and mortal procedure.Clinical ImpactNovel useful treatment solution of failed EVAR with Nellix device.

目的:本技术说明介绍了一例 Nellix 装置(Endologix,加利福尼亚州尔湾市)失效的患者,该患者被认为不适合进行开放式转换。我们计划利用定制的支路装置进行血管内修复:通过定制的四外分支装置和定制的具有倒置肢体的分叉移植物(Cook Inc.)所有分支都用戈尔 Viabahn VBX 气球扩张覆盖支架(戈尔联合公司)连接到目标血管:结论:在一名不适合进行开放手术的患者身上成功实施了血管内支架修复术,从而降低了高发病率和致命性手术的风险:临床影响:使用 Nellix 设备治疗 EVAR 失败的新型实用治疗方案。
{"title":"Endovascular Conversion of a Failed Nellix AAA-Repair by a Custom-Made Branched Device.","authors":"Baban Assaf, Martin J Austermann, Marco V Usai","doi":"10.1177/15266028241276961","DOIUrl":"10.1177/15266028241276961","url":null,"abstract":"<p><strong>Purpose: </strong>This technical note presents a case of a patient with a failed Nellix device (Endologix, Irvine, Calif) who was not deemed fit for open conversion. Our planned approach for repair involved an endovascular procedure utilizing a custom-made branched device.</p><p><strong>Technique: </strong>An endovascular repair was performed via a custom-made four outer branched device in conjunction with a custom-made bifurcated graft featuring inverted limbs (Cook Inc., Bloomington, Ind). All branches were connected to the target vessel with Gore Viabahn VBX balloon-expandable covered stents (Gore & Associates Inc.).</p><p><strong>Conclusion: </strong>Endovascular conversion with branched endovascular repair in a patient not deemed fit for open surgery was successfully performed, thereby reducing the risk of a high morbid and mortal procedure.Clinical ImpactNovel useful treatment solution of failed EVAR with Nellix device.</p>","PeriodicalId":50210,"journal":{"name":"Journal of Endovascular Therapy","volume":" ","pages":"605-608"},"PeriodicalIF":1.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142074427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intravascular Lithotripsy for Peripheral Artery Calcification: 30-Day Outcomes From the Disrupt PAD III Observational Study. 血管内碎石术治疗外周动脉钙化:破坏性 PAD III 观察性研究的 30 天结果。
IF 1.5 2区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2026-04-01 Epub Date: 2024-10-18 DOI: 10.1177/15266028241283716
Ehrin J Armstrong, George Adams, Peter A Soukas, Sarang S Mangalmurti, Nicolas W Shammas, Anderson Mehrle, Barry Bertolet, William A Gray, Gunnar Tepe, Edward Y Woo, James F McKinsey, Andrew Holden, Sahil A Parikh

Purpose: Intravascular lithotripsy (IVL) has shown promising safety and effectiveness in calcified peripheral artery disease (PAD) in large trials and small real-world experiences. Real-world evidence from a larger cohort is lacking, so we aimed to evaluate the real-world acute performance of IVL in the treatment of calcified PAD.

Materials and methods: The Disrupt PAD III Observational Study (OS) is a prospective, multicenter, single-arm study. Patients with claudication or critical limb-threatening ischemia (CLTI) and at least moderate calcification were eligible. Independent predictors of procedural outcomes were assessed by multivariable analysis.

Results: Between November 2017 and June 2021 across 30 global sites, 1373 patients with 1677 lesions (1531, 91.3% core lab evaluable) were enrolled. Diameter stenosis and lesion length was 80.6±17.6% and 93.5±74.3 mm, respectively. Target vessels included femoropopliteal (61%), iliac (15.8%), common femoral (10.7%), and infrapopliteal arteries (12.8%). Lesion characteristics included 31.1% chronic total occlusions (CTOs) and 19.3% long lesions (≥15 cm). At final assessment, residual stenosis was 23.8±11.3%, with 0.9% serious angiographic complications, no abrupt closures, distal embolization, no flow, or thrombotic events. Independent predictors of ≤30% residual stenosis were lesion length ≥15 cm (odds ratio [OR]=0.384), female sex (OR=1.850), age ≤75 years (OR=1.625), IVL balloon to artery ratio ≥1.0 (OR=1.538), and CTO lesions (OR=0.638). Lesion length ≥15 cm (OR=16.076) was an independent predictor of procedural complications.

Conclusions: The Disrupt PAD III OS represents the largest assessment of IVL periprocedural outcomes in calcified PAD. It confirmed excellent procedural safety and effectiveness in complex lesions across multiple peripheral vascular beds.Clinical ImpactThis final analysis of the PAD III OS represents the largest report of peripheral IVL utilization in daily clinical practice. The outcomes of this study indicate that previously reported procedural results in clinical trial settings can be translated to a broader patient population. Treatment with peripheral IVL in severely calcified stenotic lower limb lesions demonstrated consistent acute safety and stenosis reduction, even in complex patients across multiple vessel beds. In addition, the importance of proper IVL balloon sizing to achieve excellent acute stenosis reduction was confirmed by multivariate analysis.

目的:在大型试验和小型真实世界经验中,血管内碎石术(IVL)对钙化性外周动脉疾病(PAD)显示出良好的安全性和有效性。目前还缺乏来自更大群体的真实世界证据,因此我们旨在评估 IVL 治疗钙化 PAD 的真实世界急性期表现:Disrupt PAD III 观察性研究(OS)是一项前瞻性、多中心、单臂研究。跛行或危及肢体缺血(CLTI)且至少有中度钙化的患者均符合条件。通过多变量分析评估了手术结果的独立预测因素:2017年11月至2021年6月期间,全球30个地点的1373名患者共登记了1677个病变(1531个,91.3%的核心实验室可评估)。直径狭窄率和病变长度分别为80.6±17.6%和93.5±74.3毫米。靶血管包括股骨干动脉(61%)、髂动脉(15.8%)、股总动脉(10.7%)和膝下动脉(12.8%)。病变特征包括31.1%的慢性全闭塞(CTO)和19.3%的长病变(≥15厘米)。最终评估结果显示,残余狭窄率为(23.8±11.3)%,严重血管造影并发症为0.9%,无突然闭塞、远端栓塞、无血流或血栓事件。残余狭窄≤30%的独立预测因素是病变长度≥15厘米(比值比[OR]=0.384)、女性(OR=1.850)、年龄≤75岁(OR=1.625)、IVL球囊与动脉比值≥1.0(OR=1.538)和CTO病变(OR=0.638)。病变长度≥15厘米(OR=16.076)是手术并发症的独立预测因素:Disrupt PAD III OS是对钙化PAD IVL围手术期疗效的最大规模评估。结论:Disrupt PAD III OS 是对钙化性 PAD IVL 围手术期结果的最大规模评估,证实了在多个外周血管床的复杂病变中具有极佳的手术安全性和有效性:临床影响:PAD III OS 的最终分析是日常临床实践中使用外周 IVL 的最大规模报告。这项研究的结果表明,之前在临床试验中报告的程序结果可以应用到更广泛的患者群体中。在严重钙化的下肢狭窄病变中使用外周静脉输液治疗显示出一致的急性安全性和狭窄缩小效果,即使是跨多个血管床的复杂患者也是如此。此外,多变量分析还证实了适当的IVL球囊尺寸对实现出色的急性狭窄缩小效果的重要性。
{"title":"Intravascular Lithotripsy for Peripheral Artery Calcification: 30-Day Outcomes From the Disrupt PAD III Observational Study.","authors":"Ehrin J Armstrong, George Adams, Peter A Soukas, Sarang S Mangalmurti, Nicolas W Shammas, Anderson Mehrle, Barry Bertolet, William A Gray, Gunnar Tepe, Edward Y Woo, James F McKinsey, Andrew Holden, Sahil A Parikh","doi":"10.1177/15266028241283716","DOIUrl":"10.1177/15266028241283716","url":null,"abstract":"<p><strong>Purpose: </strong>Intravascular lithotripsy (IVL) has shown promising safety and effectiveness in calcified peripheral artery disease (PAD) in large trials and small real-world experiences. Real-world evidence from a larger cohort is lacking, so we aimed to evaluate the real-world acute performance of IVL in the treatment of calcified PAD.</p><p><strong>Materials and methods: </strong>The Disrupt PAD III Observational Study (OS) is a prospective, multicenter, single-arm study. Patients with claudication or critical limb-threatening ischemia (CLTI) and at least moderate calcification were eligible. Independent predictors of procedural outcomes were assessed by multivariable analysis.</p><p><strong>Results: </strong>Between November 2017 and June 2021 across 30 global sites, 1373 patients with 1677 lesions (1531, 91.3% core lab evaluable) were enrolled. Diameter stenosis and lesion length was 80.6±17.6% and 93.5±74.3 mm, respectively. Target vessels included femoropopliteal (61%), iliac (15.8%), common femoral (10.7%), and infrapopliteal arteries (12.8%). Lesion characteristics included 31.1% chronic total occlusions (CTOs) and 19.3% long lesions (≥15 cm). At final assessment, residual stenosis was 23.8±11.3%, with 0.9% serious angiographic complications, no abrupt closures, distal embolization, no flow, or thrombotic events. Independent predictors of ≤30% residual stenosis were lesion length ≥15 cm (odds ratio [OR]=0.384), female sex (OR=1.850), age ≤75 years (OR=1.625), IVL balloon to artery ratio ≥1.0 (OR=1.538), and CTO lesions (OR=0.638). Lesion length ≥15 cm (OR=16.076) was an independent predictor of procedural complications.</p><p><strong>Conclusions: </strong>The Disrupt PAD III OS represents the largest assessment of IVL periprocedural outcomes in calcified PAD. It confirmed excellent procedural safety and effectiveness in complex lesions across multiple peripheral vascular beds.Clinical ImpactThis final analysis of the PAD III OS represents the largest report of peripheral IVL utilization in daily clinical practice. The outcomes of this study indicate that previously reported procedural results in clinical trial settings can be translated to a broader patient population. Treatment with peripheral IVL in severely calcified stenotic lower limb lesions demonstrated consistent acute safety and stenosis reduction, even in complex patients across multiple vessel beds. In addition, the importance of proper IVL balloon sizing to achieve excellent acute stenosis reduction was confirmed by multivariate analysis.</p>","PeriodicalId":50210,"journal":{"name":"Journal of Endovascular Therapy","volume":" ","pages":"853-862"},"PeriodicalIF":1.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12972088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intravascular Lithotripsy or Atherectomy for the Common Femoral Artery? 股总动脉的血管内碎石术还是动脉粥样硬化切除术?
IF 1.5 2区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2026-04-01 Epub Date: 2024-09-28 DOI: 10.1177/15266028241284021
Grigorios Korosoglou, Tanja Böhme
{"title":"Intravascular Lithotripsy or Atherectomy for the Common Femoral Artery?","authors":"Grigorios Korosoglou, Tanja Böhme","doi":"10.1177/15266028241284021","DOIUrl":"10.1177/15266028241284021","url":null,"abstract":"","PeriodicalId":50210,"journal":{"name":"Journal of Endovascular Therapy","volume":" ","pages":"1035-1036"},"PeriodicalIF":1.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Implications of Acute Anatomic Injury After Percutaneous Renal Intervention. 经皮肾脏介入术后急性解剖损伤的影响。
IF 1.5 2区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2026-04-01 Epub Date: 2024-08-12 DOI: 10.1177/15266028241268826
Tracy J Cheun, Mark G Davies

Purpose: Percutaneous renal artery revascularization for hypertension and renal dysfunction remains common. The frequency, cause, and outcomes of anatomic injury associated with renal intervention are poorly delineated. This study aims to determine the frequency of acute anatomic renal injury after renal artery interventions, identify factors associated with anatomic renal injury, and determine whether anatomic renal injury related to renal intervention is associated with late adverse clinical events.

Methods: A retrospective analysis of patients undergoing renal artery interventions for atherosclerotic renal artery disease between 2002 and 2022 was performed. Acute anatomic renal injury encompassed renal artery dissection, renal artery perforation, acute occlusion, renal parenchymal infarction, and renal parenchymal perforation. Freedom from renal-related morbidity (increase in persistent creatinine >20% of baseline, progression to hemodialysis, death from renal-related causes) and patient survival were measured.

Results: A total of 968 patients underwent 1309 renal artery interventions: 47% for hypertension, 25% for hypertension associated with chronic renal dysfunction, and 28% for chronic renal dysfunction. An acute anatomic renal injury occurred in 5.9% of the patients. The occurrence of an anatomic injury was associated with a significant decrement in freedom from renal-related morbidity (79±2% vs 55±8%, no-injury vs injury group, mean±standard error of the mean; p=0.003) and markedly decreased survival at 5 year follow-up (78±3% vs 48±8%; p=0.002). No factor was identified that predicted anatomic injury. In those patients with anatomic injury, perforation was associated with decreased survival, while estimated glomerular filtration rate <60, resistive index >0.8, and dissection were associated with a lack of retained renal benefit.

Conclusion: Acute anatomic renal injury occurs in approximately 6% of patients undergoing percutaneous renal artery intervention and is a negative predictor of survival and is associated with subsequent renal failure, need for dialysis, and death from renal-related causes.Clinical ImpactAcute anatomic renal injury occurs in approximately 5% of patients undergoing percutaneous renal artery intervention. Modern endovascular interventions allow for the control and remediation of injuries in the majority of cases with an overall low mortality and morbidity. There is a significant early occlusion of renal arteries following the injury within 1 month. In the long term, the occurrence of injury is a negative predictor of survival and is associated with subsequent renal failure, the need for dialysis, and death from renal-related causes.

目的:经皮肾动脉血运重建治疗高血压和肾功能不全仍很常见。与肾脏介入治疗相关的解剖损伤的发生频率、原因和结果尚不明确。本研究旨在确定肾动脉介入术后急性解剖性肾损伤的频率,识别与解剖性肾损伤相关的因素,并确定与肾介入术相关的解剖性肾损伤是否与后期不良临床事件有关:对2002年至2022年间因动脉粥样硬化性肾动脉疾病接受肾动脉介入治疗的患者进行了回顾性分析。急性解剖性肾损伤包括肾动脉夹层、肾动脉穿孔、急性闭塞、肾实质梗死和肾实质穿孔。对肾脏相关发病率(持续血肌酐升高>基线的20%、进展为血液透析、肾脏相关原因导致的死亡)和患者存活率进行了测量:共有 968 名患者接受了 1309 次肾动脉介入治疗:47%的患者因高血压接受了肾动脉介入治疗,25%的患者因高血压合并慢性肾功能不全接受了肾动脉介入治疗,28%的患者因慢性肾功能不全接受了肾动脉介入治疗。5.9%的患者发生了急性解剖性肾损伤。解剖损伤的发生与肾脏相关发病率的显著下降(79±2% vs 55±8%,无损伤组 vs 损伤组,平均值±平均值的标准误差;P=0.003)和随访 5 年存活率的显著下降(78±3% vs 48±8%;P=0.002)有关。没有发现可预测解剖损伤的因素。在有解剖损伤的患者中,穿孔与存活率下降有关,而估计肾小球滤过率为0.8和夹层与缺乏保留肾脏的益处有关:急性解剖性肾损伤发生在大约 6% 接受经皮肾动脉介入治疗的患者中,是生存率的负面预测指标,与随后的肾衰竭、透析需求和肾脏相关原因导致的死亡有关:临床影响:接受经皮肾动脉介入治疗的患者中约有 5% 会出现急性解剖性肾损伤。现代血管内介入治疗可在大多数情况下控制和修复损伤,总体死亡率和发病率较低。损伤后 1 个月内,肾动脉会出现明显的早期闭塞。从长远来看,损伤的发生是存活率的负面预测因素,并与随后的肾功能衰竭、透析需求和肾脏相关原因导致的死亡有关。
{"title":"The Implications of Acute Anatomic Injury After Percutaneous Renal Intervention.","authors":"Tracy J Cheun, Mark G Davies","doi":"10.1177/15266028241268826","DOIUrl":"10.1177/15266028241268826","url":null,"abstract":"<p><strong>Purpose: </strong>Percutaneous renal artery revascularization for hypertension and renal dysfunction remains common. The frequency, cause, and outcomes of anatomic injury associated with renal intervention are poorly delineated. This study aims to determine the frequency of acute anatomic renal injury after renal artery interventions, identify factors associated with anatomic renal injury, and determine whether anatomic renal injury related to renal intervention is associated with late adverse clinical events.</p><p><strong>Methods: </strong>A retrospective analysis of patients undergoing renal artery interventions for atherosclerotic renal artery disease between 2002 and 2022 was performed. Acute anatomic renal injury encompassed renal artery dissection, renal artery perforation, acute occlusion, renal parenchymal infarction, and renal parenchymal perforation. Freedom from renal-related morbidity (increase in persistent creatinine >20% of baseline, progression to hemodialysis, death from renal-related causes) and patient survival were measured.</p><p><strong>Results: </strong>A total of 968 patients underwent 1309 renal artery interventions: 47% for hypertension, 25% for hypertension associated with chronic renal dysfunction, and 28% for chronic renal dysfunction. An acute anatomic renal injury occurred in 5.9% of the patients. The occurrence of an anatomic injury was associated with a significant decrement in freedom from renal-related morbidity (79±2% vs 55±8%, no-injury vs injury group, mean±standard error of the mean; p=0.003) and markedly decreased survival at 5 year follow-up (78±3% vs 48±8%; p=0.002). No factor was identified that predicted anatomic injury. In those patients with anatomic injury, perforation was associated with decreased survival, while estimated glomerular filtration rate <60, resistive index >0.8, and dissection were associated with a lack of retained renal benefit.</p><p><strong>Conclusion: </strong>Acute anatomic renal injury occurs in approximately 6% of patients undergoing percutaneous renal artery intervention and is a negative predictor of survival and is associated with subsequent renal failure, need for dialysis, and death from renal-related causes.Clinical ImpactAcute anatomic renal injury occurs in approximately 5% of patients undergoing percutaneous renal artery intervention. Modern endovascular interventions allow for the control and remediation of injuries in the majority of cases with an overall low mortality and morbidity. There is a significant early occlusion of renal arteries following the injury within 1 month. In the long term, the occurrence of injury is a negative predictor of survival and is associated with subsequent renal failure, the need for dialysis, and death from renal-related causes.</p>","PeriodicalId":50210,"journal":{"name":"Journal of Endovascular Therapy","volume":" ","pages":"775-783"},"PeriodicalIF":1.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141917965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Technical Aspects of Exclusive Transfemoral Route for Total Endovascular Arch Repair: A Custom-Made Device With Only Upward-Facing Inner Branches for Aortic Arch Treatment. 经股动脉途径进行全主动脉弓血管内修复的技术问题:用于主动脉弓治疗的仅有朝上内分支的定制装置。
IF 1.5 2区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2026-04-01 Epub Date: 2024-08-05 DOI: 10.1177/15266028241267734
Marcelo Ferreira, Matheus Mannarino, Rodrigo Cunha, Diego Ferreira, Luiz Fernando Capotorto, Guilherme Mannarino

Purpose: The purpose was to demonstrate a new arch endograft configuration to allow total endovascular aortic arch repair exclusive from transfemoral approach.

Technique: The custom-made multi-branched arch endograft (Cook Medical, Bloomington, Indiana) features 3 inner branches (IBs) for supra-aortic vessels incorporation and complete endovascular arch repair. Traditionally, the innominate and left carotid branches are anterograde IBs, requiring upper access for incorporation of these vessels, and the left subclavian branch is an upward-facing IB that can be incorporated from transfemoral access. We report a novel device configuration with only upward-facing IBs, allowing exclusive transfemoral route for total endovascular arch repair. Technical aspects, implantation technique, and limitations are described thoroughly.

Conclusion: Herein is described an arch endograft configuration that simplifies endovascular aortic arch repair, allowing supra-aortic vessel incorporation through a transfemoral route only. This innovative design may serve as another alternative in selected patients.Clinical ImpactThis innovative endograft design, with only upward-facing inner branches, simplifies the total endovascular aortic arch repair by allowing for a exclusively transfemoral approach. This may reduce procedural complexity and minimizes risks associated with multiple access points. It provides another alternative, particularly beneficial for selected high-risk patients for open repair, potentially expanding the applicability of endovascular treatments for aortic arch pathologies.

目的:旨在展示一种新的拱形内植物配置,以实现完全的主动脉弓血管内修复,而无需经股动脉途径:定制的多分支主动脉弓内膜移植物(Cook Medical, Bloomington, Indiana)具有3个内膜分支(IB),用于合并主动脉上血管和完整的主动脉弓血管内膜修复。传统上,髂内支和左颈动脉支是前向内支,需要从上部入路才能纳入这些血管,而左锁骨下支是上向内支,可以从经股动脉入路纳入。我们报告了一种仅有上行 IB 的新型设备配置,它允许经口途径进行全血管内弓修复。我们对技术方面、植入技术和局限性进行了详细描述:结论:本文描述了一种拱形内移植物配置,它简化了主动脉弓的血管内修复,只允许通过经口途径纳入主动脉上血管。这种创新设计可作为选定患者的另一种选择:临床影响:这一创新的内植物设计只有朝上的内侧分支,简化了血管内主动脉弓总修复术,只允许经口途径。这可以降低手术的复杂性,并最大限度地减少与多个接入点相关的风险。它提供了另一种选择,尤其有利于选定的高风险患者进行开放式修复,有可能扩大主动脉弓病变的血管内治疗的适用范围。
{"title":"Technical Aspects of Exclusive Transfemoral Route for Total Endovascular Arch Repair: A Custom-Made Device With Only Upward-Facing Inner Branches for Aortic Arch Treatment.","authors":"Marcelo Ferreira, Matheus Mannarino, Rodrigo Cunha, Diego Ferreira, Luiz Fernando Capotorto, Guilherme Mannarino","doi":"10.1177/15266028241267734","DOIUrl":"10.1177/15266028241267734","url":null,"abstract":"<p><strong>Purpose: </strong>The purpose was to demonstrate a new arch endograft configuration to allow total endovascular aortic arch repair exclusive from transfemoral approach.</p><p><strong>Technique: </strong>The custom-made multi-branched arch endograft (Cook Medical, Bloomington, Indiana) features 3 inner branches (IBs) for supra-aortic vessels incorporation and complete endovascular arch repair. Traditionally, the innominate and left carotid branches are anterograde IBs, requiring upper access for incorporation of these vessels, and the left subclavian branch is an upward-facing IB that can be incorporated from transfemoral access. We report a novel device configuration with only upward-facing IBs, allowing exclusive transfemoral route for total endovascular arch repair. Technical aspects, implantation technique, and limitations are described thoroughly.</p><p><strong>Conclusion: </strong>Herein is described an arch endograft configuration that simplifies endovascular aortic arch repair, allowing supra-aortic vessel incorporation through a transfemoral route only. This innovative design may serve as another alternative in selected patients.Clinical ImpactThis innovative endograft design, with only upward-facing inner branches, simplifies the total endovascular aortic arch repair by allowing for a exclusively transfemoral approach. This may reduce procedural complexity and minimizes risks associated with multiple access points. It provides another alternative, particularly beneficial for selected high-risk patients for open repair, potentially expanding the applicability of endovascular treatments for aortic arch pathologies.</p>","PeriodicalId":50210,"journal":{"name":"Journal of Endovascular Therapy","volume":" ","pages":"598-604"},"PeriodicalIF":1.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141890691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Total Endovascular Repair of a Giant Iliac Vein Aneurysm: A Case Report and Review of Literature. 巨大髂静脉动脉瘤的全血管内修复术:病例报告和文献综述。
IF 1.5 2区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2026-04-01 Epub Date: 2024-06-16 DOI: 10.1177/15266028241261661
Dimitrios A Chatzelas, Apostolos G Pitoulias, Georgios V Tsamourlidis, Theodosia N Zampaka, Anastasios G Potouridis, Maria D Tachtsi, Georgios A Pitoulias

Purpose: The iliac veins are the least frequent location for venous aneurysms, with only a few cases described globally. The etiology and clinical presentation of this extremely rare entity is diverse and unclear and no treatment consensus has been reached yet. Our purpose is to present an interesting iliac vein aneurysm (IVA) case that we treated in our department, with a brief review of the literature.

Case report: We report a case of a 74-year-old male patient with a giant, 55 mm in diameter, asymptomatic, right common IVA, with concurrent aplasia of the left common iliac vein and an extensive network of venous collaterals. The patient was treated, under general anesthesia, with total endovascular iliocaval reconstruction through implantation of a 32 × 100 mm thoracic aortic tubular Ankura stent graft. The computed tomography venography at first-month follow-up showed the complete exclusion of the IVA, without any endoleak and the patient remains up to date free of symptoms and thromboembolic events.

Conclusion: Twelve cases of endovascular treatment of IVA have been reported so far, and our case is the first with implantation of a thoracic aortic stent graft. Our results suggest that this technique is safe, effective, and may be considered for appropriately selected patients.Clinical ImpactThis is the first case with total endovascular repair of an iliac vein aneurysm with contralateral iliac vein aplasia through endovenous implantation of a thoracic aortic stent-graft. Our results suggest that this technique is safe and effective and thus, may be considered for appropriately selected cases.

目的:髂静脉是静脉瘤发生率最低的部位,全球仅有几例。这种极为罕见的疾病的病因和临床表现多种多样,尚不明确,治疗方法也尚未达成共识。我们的目的是介绍我们科室治疗的一例有趣的髂静脉动脉瘤(IVA)病例,并对文献进行简要回顾:我们报告了一例 74 岁男性患者的病例,他患有直径 55 毫米、无症状的巨大右髂总静脉瘤,同时伴有左髂总静脉增生和广泛的静脉袢网。患者在全身麻醉的情况下,通过植入 32 × 100 毫米的胸主动脉管状安库拉支架移植物,接受了全血管内髂腹腔重建术。随访一个月后的计算机断层扫描静脉造影显示,静脉腔完全闭塞,没有任何内漏,患者至今没有任何症状和血栓栓塞事件:迄今为止,已有 12 例血管内治疗 IVA 的报道,而我们的病例是第一例植入胸主动脉支架移植物的病例。我们的研究结果表明,这项技术安全、有效,经过适当选择的患者可以考虑采用:这是首例通过静脉内植入胸主动脉支架移植物,对伴有对侧髂静脉增生的髂静脉动脉瘤进行全血管内修复的病例。我们的研究结果表明,这项技术安全有效,因此可以考虑用于经过适当选择的病例。
{"title":"Total Endovascular Repair of a Giant Iliac Vein Aneurysm: A Case Report and Review of Literature.","authors":"Dimitrios A Chatzelas, Apostolos G Pitoulias, Georgios V Tsamourlidis, Theodosia N Zampaka, Anastasios G Potouridis, Maria D Tachtsi, Georgios A Pitoulias","doi":"10.1177/15266028241261661","DOIUrl":"10.1177/15266028241261661","url":null,"abstract":"<p><strong>Purpose: </strong>The iliac veins are the least frequent location for venous aneurysms, with only a few cases described globally. The etiology and clinical presentation of this extremely rare entity is diverse and unclear and no treatment consensus has been reached yet. Our purpose is to present an interesting iliac vein aneurysm (IVA) case that we treated in our department, with a brief review of the literature.</p><p><strong>Case report: </strong>We report a case of a 74-year-old male patient with a giant, 55 mm in diameter, asymptomatic, right common IVA, with concurrent aplasia of the left common iliac vein and an extensive network of venous collaterals. The patient was treated, under general anesthesia, with total endovascular iliocaval reconstruction through implantation of a 32 × 100 mm thoracic aortic tubular Ankura stent graft. The computed tomography venography at first-month follow-up showed the complete exclusion of the IVA, without any endoleak and the patient remains up to date free of symptoms and thromboembolic events.</p><p><strong>Conclusion: </strong>Twelve cases of endovascular treatment of IVA have been reported so far, and our case is the first with implantation of a thoracic aortic stent graft. Our results suggest that this technique is safe, effective, and may be considered for appropriately selected patients.Clinical ImpactThis is the first case with total endovascular repair of an iliac vein aneurysm with contralateral iliac vein aplasia through endovenous implantation of a thoracic aortic stent-graft. Our results suggest that this technique is safe and effective and thus, may be considered for appropriately selected cases.</p>","PeriodicalId":50210,"journal":{"name":"Journal of Endovascular Therapy","volume":" ","pages":"1020-1024"},"PeriodicalIF":1.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141332390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bilateral Congenital Pelvic Arteriovenous Malformation: A Case Report and Review of Literature. 双侧先天性盆腔动静脉畸形:病例报告和文献综述。
IF 1.5 2区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2026-04-01 Epub Date: 2024-08-06 DOI: 10.1177/15266028241267747
Margherita Viglione, Andrea Discalzi, Francesco Mistretta, Andrea Mancini, Floriana Nardelli, Mauro Bergui

Purpose: Through a paradigmatic case and a systematic literature review, we present various endovascular strategies for treating pelvic paravesical arteriovenous vascular malformations (AVMs), with a focus on the efficacy of accessing the shunt point through direct puncture of the venous collector.

Case report: A 42-year-old male with nonspecific pelvic pain underwent a computed tomography (CT) scan, which revealed bilateral pelvic AVMs characterized by a network of arteriolar afferents originating from the internal iliac arteries and the inferior mesenteric artery, draining into 2 interconnected giant venous sacs in the bilateral paravesical space. The malformation was classified as type II according to the Cho classification. Following an unsuccessful attempt at transarterial embolization, we devised a plan for bilateral transvenous embolization in 2 separate sessions. Venous access was achieved through percutaneous transperineal ultrasound-guided puncture of the dominant outflow venous sac. A microcatheter was then placed directly into the shunt point, where sclerosant and embolic agents were specifically delivered. Follow-up imaging showed complete obliteration of both pelvic AVMs.

Conclusions: Effective hemostasis of pelvic paravesical AVMs can be achieved by targeting the shunt point from the aneurysmal dominant outflow vein, potentially through direct percutaneous puncture.Clinical ImpactThis study aims to demonstrate the effectiveness of a transvenous approach in cases of embolization of pelvic paravesical arteriovenous vascular malformations (AVMs). The key to successful treatment lies in occluding the shunt point within the aneurysmal dominant outflow vein's wall, which can be reached transvenously and potentially through direct percutaneous puncture. Although arterial occlusion can be performed additionally, it should not be performed alone due to its higher risk of AVM persistence/recurrence.

目的:通过一个典型病例和系统的文献综述,我们介绍了治疗盆腔旁动静脉血管畸形(AVM)的各种血管内治疗策略,重点介绍了通过直接穿刺静脉收集器进入分流点的疗效:一名患有非特异性盆腔疼痛的 42 岁男性接受了计算机断层扫描(CT),结果发现双侧盆腔动静脉畸形,其特点是动脉传入网络源自髂内动脉和肠系膜下动脉,在双侧腹股沟旁间隙排入两个相互连接的巨大静脉囊。根据赵氏分类法,该畸形被归为II型。经动脉栓塞尝试失败后,我们制定了一个计划,分两次进行双侧经静脉栓塞。通过经皮经会阴超声引导穿刺优势流出静脉囊,实现静脉入路。然后,将微导管直接插入分流点,并在此注射硬化剂和栓塞剂。随访造影显示,两个盆腔动静脉畸形均已完全消失:结论:通过直接经皮穿刺,以动脉瘤主导流出静脉的分流点为目标,可实现盆腔旁动静脉畸形的有效止血:本研究旨在证明经静脉栓塞盆腔旁动静脉血管畸形(AVM)病例的有效性。成功治疗的关键在于闭塞动脉瘤显性流出静脉壁内的分流点,经静脉或直接经皮穿刺均可到达该点。虽然动脉闭塞可以额外进行,但由于 AVM 持续存在/复发的风险较高,因此不应单独进行动脉闭塞。
{"title":"Bilateral Congenital Pelvic Arteriovenous Malformation: A Case Report and Review of Literature.","authors":"Margherita Viglione, Andrea Discalzi, Francesco Mistretta, Andrea Mancini, Floriana Nardelli, Mauro Bergui","doi":"10.1177/15266028241267747","DOIUrl":"10.1177/15266028241267747","url":null,"abstract":"<p><strong>Purpose: </strong>Through a paradigmatic case and a systematic literature review, we present various endovascular strategies for treating pelvic paravesical arteriovenous vascular malformations (AVMs), with a focus on the efficacy of accessing the shunt point through direct puncture of the venous collector.</p><p><strong>Case report: </strong>A 42-year-old male with nonspecific pelvic pain underwent a computed tomography (CT) scan, which revealed bilateral pelvic AVMs characterized by a network of arteriolar afferents originating from the internal iliac arteries and the inferior mesenteric artery, draining into 2 interconnected giant venous sacs in the bilateral paravesical space. The malformation was classified as type II according to the Cho classification. Following an unsuccessful attempt at transarterial embolization, we devised a plan for bilateral transvenous embolization in 2 separate sessions. Venous access was achieved through percutaneous transperineal ultrasound-guided puncture of the dominant outflow venous sac. A microcatheter was then placed directly into the shunt point, where sclerosant and embolic agents were specifically delivered. Follow-up imaging showed complete obliteration of both pelvic AVMs.</p><p><strong>Conclusions: </strong>Effective hemostasis of pelvic paravesical AVMs can be achieved by targeting the shunt point from the aneurysmal dominant outflow vein, potentially through direct percutaneous puncture.Clinical ImpactThis study aims to demonstrate the effectiveness of a transvenous approach in cases of embolization of pelvic paravesical arteriovenous vascular malformations (AVMs). The key to successful treatment lies in occluding the shunt point within the aneurysmal dominant outflow vein's wall, which can be reached transvenously and potentially through direct percutaneous puncture. Although arterial occlusion can be performed additionally, it should not be performed alone due to its higher risk of AVM persistence/recurrence.</p>","PeriodicalId":50210,"journal":{"name":"Journal of Endovascular Therapy","volume":" ","pages":"543-554"},"PeriodicalIF":1.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141898760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk Factors for Adverse In-Hospital Outcomes in Patients With Traumatic Blunt Thoracic Aortic Injuries Undergoing Thoracic Endovascular Aortic Repair (TEVAR): An Analysis of the US Nationwide Inpatient Sample. 接受胸腔内血管主动脉修复术 (TEVAR) 的创伤性钝性胸主动脉损伤患者不良院内预后的风险因素:美国全国住院患者样本分析》。
IF 1.5 2区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2026-04-01 Epub Date: 2024-08-26 DOI: 10.1177/15266028241271732
Po-Sung Chen, Kuo-Jen Lo, Chi-Hsiu Yu, Chi-Feng Wang, Chuin-I Lee

Purpose: Thoracic endovascular aortic repair (TEVAR) is a treatment for traumatic blunt thoracic aortic injury (BTAI) with good survival rates and safety. However, there is limited study on the risk factors for in-hospital mortality and complications. This study aimed to identify risk factors associated with poor in-hospital outcomes after TEVAR.

Materials and methods: This is a population-based, retrospective observational study. Data of adults ≥20 years admitted for BTAI who received TEVAR were extracted from the Nationwide Inpatient Sample (NIS) database 2005 to 2018. The primary outcome was in-hospital mortality, and the secondary outcomes were length of stay (LOS) and unfavorable discharge (ie, non-routine discharge, including nursing homes or long-term care facilities). Associations between study variables and in-hospital outcomes were determined using univariate and multivariable logistic and linear regression analyses.

Results: Data of 1095 participants (representing 5360 hospitalized patients in the United States) were analyzed. Multivariable analysis revealed that older age (adjusted odds ratio [aOR]=1.02) and having at least 1 perioperative complication (aOR=4.01) were significantly associated with increased risk for in-hospital mortality. Patients with at least 1 perioperative complication (aOR=11.19) had significantly increased odds for prolonged LOS. Risk for unfavorable discharge was significantly increased by older age (aOR=1.02), household income at quartile 2 (aOR=1.58), Charlson Comorbidity Index (CCI) 2 to 3 (aOR=1.66), and having at least 1 complication (aOR=3.94). Complications including perioperative cerebrovascular accident (CVA) (aOR=2.75), venous thromboembolism (VTE) (aOR=2.87), pneumonia (aOR=3.93), sepsis (aOR=4.69), infection (aOR=4.49), respiratory failure (aOR=4.55), mechanical ventilation (aOR=3.27), and acute kidney injury (AKI) (aOR=3.09) significantly predicted prolonged LOS.

Conclusions: In adults with traumatic BTAI undergoing TEVAR, advanced age and perioperative complications are risk factors for poor in-hospital outcomes. Acute kidney injury, CVA, respiratory failure, and sepsis are strong predictors of prolonged LOS, unfavorable discharge, and in-hospital mortality.Clinical ImpactThe study identifies advanced age and perioperative complications as key risk factors for poor in-hospital outcomes in patients undergoing TEVAR for BTAI. Clinicians should be vigilant in managing these patients, particularly those with comorbidities, to mitigate risks. The findings suggest a need for tailored perioperative care strategies to improve survival rates and reduce complications. This research highlights the critical importance of early identification and intervention in high-risk patients, offering an innovative approach to refining TEVAR protocols and enhancing patient outcomes in trauma care.

目的:胸腔内血管主动脉修复术(TEVAR)是治疗创伤性钝性胸主动脉损伤(BTAI)的一种方法,具有良好的存活率和安全性。然而,关于院内死亡率和并发症风险因素的研究十分有限。本研究旨在确定与 TEVAR 术后院内不良预后相关的风险因素:这是一项基于人群的回顾性观察研究。从2005年至2018年的全国住院患者样本(NIS)数据库中提取了因BTAI入院并接受TEVAR的≥20岁成人的数据。主要结局是院内死亡率,次要结局是住院时间(LOS)和不利出院(即非例行出院,包括疗养院或长期护理机构)。采用单变量和多变量逻辑回归分析及线性回归分析确定研究变量与住院结果之间的关系:对 1095 名参与者(代表美国 5360 名住院患者)的数据进行了分析。多变量分析表明,年龄较大(调整后赔率[aOR]=1.02)和至少有一种围手术期并发症(aOR=4.01)与院内死亡风险增加显著相关。至少有一种围手术期并发症(aOR=11.19)的患者住院时间延长的几率明显增加。年龄较大(aOR=1.02)、家庭收入处于第2分位数(aOR=1.58)、夏尔森综合症指数(CCI)为2至3(aOR=1.66)以及至少患有一种并发症(aOR=3.94)的患者出院不利的风险明显增加。并发症包括围手术期脑血管意外(CVA)(aOR=2.75)、静脉血栓栓塞(VTE)(aOR=2.87)、肺炎(aOR=3.93)、败血症(aOR=4.69)、感染(aOR=4.49)、呼吸衰竭(aOR=4.55)、机械通气(aOR=3.27)和急性肾损伤(AKI)(aOR=3.09)显著预示着LOS的延长:在接受TEVAR手术的外伤性BTAI成人患者中,高龄和围手术期并发症是导致不良住院预后的危险因素。急性肾损伤、CVA、呼吸衰竭和脓毒症是住院时间延长、不利出院和院内死亡率的有力预测因素:临床影响:该研究发现,高龄和围手术期并发症是因 BTAI 而接受 TEVAR 手术的患者出现不良院内预后的关键风险因素。临床医生在管理这些患者,尤其是合并症患者时应保持警惕,以降低风险。研究结果表明,有必要制定有针对性的围手术期护理策略,以提高存活率并减少并发症。这项研究强调了早期识别和干预高风险患者的重要性,为完善 TEVAR 方案和提高创伤护理中的患者预后提供了一种创新方法。
{"title":"Risk Factors for Adverse In-Hospital Outcomes in Patients With Traumatic Blunt Thoracic Aortic Injuries Undergoing Thoracic Endovascular Aortic Repair (TEVAR): An Analysis of the US Nationwide Inpatient Sample.","authors":"Po-Sung Chen, Kuo-Jen Lo, Chi-Hsiu Yu, Chi-Feng Wang, Chuin-I Lee","doi":"10.1177/15266028241271732","DOIUrl":"10.1177/15266028241271732","url":null,"abstract":"<p><strong>Purpose: </strong>Thoracic endovascular aortic repair (TEVAR) is a treatment for traumatic blunt thoracic aortic injury (BTAI) with good survival rates and safety. However, there is limited study on the risk factors for in-hospital mortality and complications. This study aimed to identify risk factors associated with poor in-hospital outcomes after TEVAR.</p><p><strong>Materials and methods: </strong>This is a population-based, retrospective observational study. Data of adults ≥20 years admitted for BTAI who received TEVAR were extracted from the Nationwide Inpatient Sample (NIS) database 2005 to 2018. The primary outcome was in-hospital mortality, and the secondary outcomes were length of stay (LOS) and unfavorable discharge (ie, non-routine discharge, including nursing homes or long-term care facilities). Associations between study variables and in-hospital outcomes were determined using univariate and multivariable logistic and linear regression analyses.</p><p><strong>Results: </strong>Data of 1095 participants (representing 5360 hospitalized patients in the United States) were analyzed. Multivariable analysis revealed that older age (adjusted odds ratio [aOR]=1.02) and having at least 1 perioperative complication (aOR=4.01) were significantly associated with increased risk for in-hospital mortality. Patients with at least 1 perioperative complication (aOR=11.19) had significantly increased odds for prolonged LOS. Risk for unfavorable discharge was significantly increased by older age (aOR=1.02), household income at quartile 2 (aOR=1.58), Charlson Comorbidity Index (CCI) 2 to 3 (aOR=1.66), and having at least 1 complication (aOR=3.94). Complications including perioperative cerebrovascular accident (CVA) (aOR=2.75), venous thromboembolism (VTE) (aOR=2.87), pneumonia (aOR=3.93), sepsis (aOR=4.69), infection (aOR=4.49), respiratory failure (aOR=4.55), mechanical ventilation (aOR=3.27), and acute kidney injury (AKI) (aOR=3.09) significantly predicted prolonged LOS.</p><p><strong>Conclusions: </strong>In adults with traumatic BTAI undergoing TEVAR, advanced age and perioperative complications are risk factors for poor in-hospital outcomes. Acute kidney injury, CVA, respiratory failure, and sepsis are strong predictors of prolonged LOS, unfavorable discharge, and in-hospital mortality.Clinical ImpactThe study identifies advanced age and perioperative complications as key risk factors for poor in-hospital outcomes in patients undergoing TEVAR for BTAI. Clinicians should be vigilant in managing these patients, particularly those with comorbidities, to mitigate risks. The findings suggest a need for tailored perioperative care strategies to improve survival rates and reduce complications. This research highlights the critical importance of early identification and intervention in high-risk patients, offering an innovative approach to refining TEVAR protocols and enhancing patient outcomes in trauma care.</p>","PeriodicalId":50210,"journal":{"name":"Journal of Endovascular Therapy","volume":" ","pages":"767-774"},"PeriodicalIF":1.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142057165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes of a Multidisciplinary Vascular Practice: 12-Month Amputation-Free Survival and Beyond in Patients With Chronic Limb-Threatening Ischemia. 多学科血管实践的成果:慢性肢体危重缺血患者 12 个月无截肢生存期及以后的情况。
IF 1.5 2区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2026-04-01 Epub Date: 2024-09-05 DOI: 10.1177/15266028241276328
Ramkrishna A Patel, Brooke Fallon, Aaron Brandis, Kane Chang, Arthur J Demarsico, Kamal F Kassis, Christopher Kim, Kevin S Lopyan, Bridgette McCabe, Rajesh I Patel, Matthew S Samra, Michael J Schmidling, Mike Watts, Nicholas Petruzzi

Objective: There is great variability in the treatment of chronic limb-threatening ischemia, including the practice paradigm, vascular provider specialty, devices utilized, and experience with advanced open and/or endovascular treatments, among other factors. Our unique practice consists of patient-centered, clinically oriented Interventional Radiologists and Vascular Surgeons, with treatments being performed in Office Interventional Suites (OIS), Ambulatory surgery center (ASC), and hospital inpatient/outpatient settings. We evaluate our results, centered on major amputation rates while comparing case complexity and rates with previously published data.

Methods: A retrospective review was performed of all Rutherford 4, 5, and 6 patients who underwent treatment in our practice from 2015 to 2021. Baseline patient characteristics, complexity of lesions, and major amputation rates were collected. Patients with more complex diseases or requiring re-interventions were openly discussed in multidisciplinary fashion to determine the group's approach to revascularization. Limb salvage, clinically driven target lesion revascularization (TLR), repeat interventions, length of follow-up, and mortality were assessed.

Results: Treatment was performed in 829 limbs in 351 females and 478 males, with chronic limb-threatening ischemia. Of the 829 cases, 541 cases had at least 1 chronic total occlusion (CTO), including 115 limbs with 2 CTOs and 24 limbs with 3 CTOs with 63.5% of cases requiring multilevel intervention. One year mortality rate was 6.2% with a major lower extremity amputation rate of 2.3% with a mean length of follow-up of 22.3 months. One-year freedom from clinically driven TLR rate was 78.7% with repeat intervention in 163 cases within 12 months. Over the course of the study, within the femoropopliteal stent subset, there was a significant increase in time to reintervention when newer stent technologies were utilized such as woven nitinol and drug-eluting technology (p=0.03). The overall 1-year amputation-free survival (AFS) was 91.5%Conclusions:Multidisciplinary approach with surgical and endovascular treatment may provide patients with the best chance of AFS.Clinical ImpactReal world practice of critical limb-threatening ischemia in a multidisciplinary practice demonstrates favorable outcomes for patients with the best reported one year major amputation free survival in a population this large. A strong clinical practice based on close routine follow up and arterial duplex monitoring is a major contributing factor, as well as utilization of the latest technology in drug eluting stents and drug coated balloons for best patient outcomes. We hope this study provides other practices with a guideline for establishing or modifying their practice to attain the best procedural and clinical outcomes.

目的:慢性肢体缺血的治疗方法千差万别,其中包括诊疗模式、血管提供者的专业、使用的设备以及先进的开放式和/或血管内治疗经验等因素。我们的独特实践由以患者为中心、以临床为导向的介入放射科医生和血管外科医生组成,治疗在办公室介入室(OIS)、非卧床手术中心(ASC)和医院住院/门诊环境中进行。我们对结果进行了评估,重点是主要截肢率,同时将病例复杂程度和截肢率与之前公布的数据进行比较:我们对 2015 年至 2021 年期间在本诊所接受治疗的所有卢瑟福 4、5 和 6 型患者进行了回顾性审查。收集了患者的基线特征、病变复杂程度和主要截肢率。对病情较复杂或需要再次干预的患者进行了多学科公开讨论,以确定该小组的血管再通方法。对肢体挽救、临床驱动的靶病变血管再通(TLR)、重复干预、随访时间和死亡率进行了评估:结果:对患有慢性肢体缺血的 829 条肢体进行了治疗,其中女性 351 条,男性 478 条。在829个病例中,541个病例至少有一个慢性全闭塞(CTO),其中115个肢体有2个CTO,24个肢体有3个CTO,63.5%的病例需要多级干预。一年的死亡率为 6.2%,主要下肢截肢率为 2.3%,平均随访时间为 22.3 个月。一年内无临床症状的 TLR 发生率为 78.7%,163 例患者在 12 个月内接受了重复干预。在研究过程中,在股骨腘动脉支架子集中,如果采用较新的支架技术,如编织镍钛诺和药物洗脱技术,再介入时间会显著增加(P=0.03)。总体1年无截肢生存率(AFS)为91.5:手术和血管内治疗的多学科方法可为患者提供最佳的无截肢生存机会:临床影响:在多学科治疗危重肢体缺血的真实实践中,患者获得了良好的治疗效果,在如此庞大的人群中,一年无截肢存活率达到了最高水平。基于密切的常规随访和动脉双相监测的强大临床实践是一个主要因素,同时,利用药物洗脱支架和药物涂层球囊的最新技术也能为患者带来最佳治疗效果。我们希望这项研究能为其他临床实践提供指导,帮助他们建立或改进自己的实践,以获得最佳的手术和临床效果。
{"title":"Outcomes of a Multidisciplinary Vascular Practice: 12-Month Amputation-Free Survival and Beyond in Patients With Chronic Limb-Threatening Ischemia.","authors":"Ramkrishna A Patel, Brooke Fallon, Aaron Brandis, Kane Chang, Arthur J Demarsico, Kamal F Kassis, Christopher Kim, Kevin S Lopyan, Bridgette McCabe, Rajesh I Patel, Matthew S Samra, Michael J Schmidling, Mike Watts, Nicholas Petruzzi","doi":"10.1177/15266028241276328","DOIUrl":"10.1177/15266028241276328","url":null,"abstract":"<p><strong>Objective: </strong>There is great variability in the treatment of chronic limb-threatening ischemia, including the practice paradigm, vascular provider specialty, devices utilized, and experience with advanced open and/or endovascular treatments, among other factors. Our unique practice consists of patient-centered, clinically oriented Interventional Radiologists and Vascular Surgeons, with treatments being performed in Office Interventional Suites (OIS), Ambulatory surgery center (ASC), and hospital inpatient/outpatient settings. We evaluate our results, centered on major amputation rates while comparing case complexity and rates with previously published data.</p><p><strong>Methods: </strong>A retrospective review was performed of all Rutherford 4, 5, and 6 patients who underwent treatment in our practice from 2015 to 2021. Baseline patient characteristics, complexity of lesions, and major amputation rates were collected. Patients with more complex diseases or requiring re-interventions were openly discussed in multidisciplinary fashion to determine the group's approach to revascularization. Limb salvage, clinically driven target lesion revascularization (TLR), repeat interventions, length of follow-up, and mortality were assessed.</p><p><strong>Results: </strong>Treatment was performed in 829 limbs in 351 females and 478 males, with chronic limb-threatening ischemia. Of the 829 cases, 541 cases had at least 1 chronic total occlusion (CTO), including 115 limbs with 2 CTOs and 24 limbs with 3 CTOs with 63.5% of cases requiring multilevel intervention. One year mortality rate was 6.2% with a major lower extremity amputation rate of 2.3% with a mean length of follow-up of 22.3 months. One-year freedom from clinically driven TLR rate was 78.7% with repeat intervention in 163 cases within 12 months. Over the course of the study, within the femoropopliteal stent subset, there was a significant increase in time to reintervention when newer stent technologies were utilized such as woven nitinol and drug-eluting technology (p=0.03). The overall 1-year amputation-free survival (AFS) was 91.5%Conclusions:Multidisciplinary approach with surgical and endovascular treatment may provide patients with the best chance of AFS.Clinical ImpactReal world practice of critical limb-threatening ischemia in a multidisciplinary practice demonstrates favorable outcomes for patients with the best reported one year major amputation free survival in a population this large. A strong clinical practice based on close routine follow up and arterial duplex monitoring is a major contributing factor, as well as utilization of the latest technology in drug eluting stents and drug coated balloons for best patient outcomes. We hope this study provides other practices with a guideline for establishing or modifying their practice to attain the best procedural and clinical outcomes.</p>","PeriodicalId":50210,"journal":{"name":"Journal of Endovascular Therapy","volume":" ","pages":"805-813"},"PeriodicalIF":1.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142134312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Maximal Systolic Acceleration and Near-Infrared Fluorescence Imaging With Indocyanine Green as Predictors for Successful Lower Extremity Revascularization. 最大收缩加速度和吲哚青绿近红外荧光成像作为下肢血管再通手术成功的预测指标
IF 1.5 2区 医学 Q3 PERIPHERAL VASCULAR DISEASE Pub Date : 2026-04-01 Epub Date: 2024-09-05 DOI: 10.1177/15266028241274568
Mo W Kruiswijk, Siem A Willems, Stefan Koning, Floris P Tange, Jeroen J W M Brouwers, Roderick C Peul, Jan van Schaik, Abbey Schepers, Jaap Hamming, Koen E A van der Bogt, Carla S P van Rijswijk, Alexander L Vahrmeijer, Pim van den Hoven, Joost R van der Vorst

Background: Patients with lower extremity arterial disease (LEAD) frequently require revascularization procedures. Currently used diagnostic methods are insufficient in predicting successful outcomes and focus on macrovascular rather than microvascular state. Several promising modalities to increase diagnostic accuracy are emerging, including maximal systolic acceleration (ACCmax), measured by duplex ultrasound (DUS). For the assessment of tissue perfusion, near-infrared fluorescence (NIR) imaging using indocyanine green (ICG) demonstrates promising results. This study aims to identify the usefulness of combining these two methods for macrovascular and microvascular perfusion assessment to predict successful clinical outcomes.

Methods: A retrospective study was performed collecting preinterventional and postinterventional DUS and ICG NIR fluorescence imaging measurements from LEAD patients undergoing revascularization. The correlation between the preinterventional and postinterventional perfusion parameters, described as the delta (Δ) ACCmax and ΔICG NIR fluorescence parameters, were analyzed. Improvements in perfusion parameters were compared to clinical outcomes, defined as improvement in pain-free walking distance, freedom from rest pain, or tendency toward wound and ulcer healing.

Results: A total of 38 patients (42 limbs) were included. ACCmax and ICG NIR fluorescence perfusion parameters improved significantly after revascularization (p<0.001). Patients with a poor clinical outcome had a significantly lower improvement of both parameters after revascularization (p<0.001-0.016). Lack of correlation was found between the delta of ACCmax and ICG NIR fluorescence imaging. Multiple non-congruent improvements of macrovascular parameters (ACCmax) and perfusion (ICG NIR fluorescence) were seen within patients. However, for all patients with a successful clinical outcome, at least one parameter improved.

Conclusion: Combining ACCmax and ICG NIR fluorescence imaging revealed improvement in at least one parameter within all patients with a successful clinical outcome. This study highlights the potential of assessing both the macrovascular state and tissue perfusion following lower extremity revascularization, as both appear to reflect different aspects of vascularization.Clinical ImpactNumerous techniques have been developed to assess tissue perfusion to predict clinical outcomes following revascularization in patients with peripheral artery disease. However, none are widely implemented in clinical practice. This study emphasized the importance of employing multiple modalities from different perspectives for more accurate prediction. By focusing on both the macrovascular state and tissue perfusion, clinicians can better guide themselves in their treatment strategies.

背景:下肢动脉疾病(LEAD)患者经常需要进行血管重建手术。目前使用的诊断方法不足以预测成功的结果,而且只关注大血管而非微血管状态。目前正在出现几种有望提高诊断准确性的方法,包括通过双工超声(DUS)测量最大收缩加速度(ACCmax)。在评估组织灌注方面,使用吲哚青绿(ICG)的近红外荧光(NIR)成像显示出良好的效果。本研究旨在确定结合这两种方法进行大血管和微血管灌注评估对预测成功的临床结果是否有用:一项回顾性研究收集了接受血管重建手术的 LEAD 患者的介入前和介入后 DUS 和 ICG 近红外荧光成像测量结果。分析了介入前和介入后灌注参数(即 ACCmax Δ和 ICG NIR 荧光参数Δ)之间的相关性。灌注参数的改善与临床结果进行了比较,临床结果的定义是无痛行走距离的改善、无静息痛或伤口和溃疡愈合的趋势:结果:共纳入 38 名患者(42 条肢体)。血管再通后,ACCmax 和 ICG 近红外荧光灌注参数明显改善(pmax 和 ICG 近红外荧光成像)。患者的大血管参数(ACCmax)和灌注参数(ICG 近红外荧光)有多种不一致的改善。然而,在所有临床结果良好的患者中,至少有一项参数得到了改善:结论:结合 ACCmax 和 ICG 近红外荧光成像,所有临床效果良好的患者至少有一项参数得到改善。这项研究强调了评估下肢血管再通后大血管状态和组织灌注的潜力,因为两者似乎反映了血管形成的不同方面:临床影响:目前已开发出许多评估组织灌注的技术,用于预测外周动脉疾病患者血管再通后的临床结果。然而,这些技术都没有在临床实践中得到广泛应用。这项研究强调了从不同角度采用多种模式进行更准确预测的重要性。通过同时关注大血管状态和组织灌注,临床医生可以更好地指导自己的治疗策略。
{"title":"Maximal Systolic Acceleration and Near-Infrared Fluorescence Imaging With Indocyanine Green as Predictors for Successful Lower Extremity Revascularization.","authors":"Mo W Kruiswijk, Siem A Willems, Stefan Koning, Floris P Tange, Jeroen J W M Brouwers, Roderick C Peul, Jan van Schaik, Abbey Schepers, Jaap Hamming, Koen E A van der Bogt, Carla S P van Rijswijk, Alexander L Vahrmeijer, Pim van den Hoven, Joost R van der Vorst","doi":"10.1177/15266028241274568","DOIUrl":"10.1177/15266028241274568","url":null,"abstract":"<p><strong>Background: </strong>Patients with lower extremity arterial disease (LEAD) frequently require revascularization procedures. Currently used diagnostic methods are insufficient in predicting successful outcomes and focus on macrovascular rather than microvascular state. Several promising modalities to increase diagnostic accuracy are emerging, including maximal systolic acceleration (ACC<sub>max</sub>), measured by duplex ultrasound (DUS). For the assessment of tissue perfusion, near-infrared fluorescence (NIR) imaging using indocyanine green (ICG) demonstrates promising results. This study aims to identify the usefulness of combining these two methods for macrovascular and microvascular perfusion assessment to predict successful clinical outcomes.</p><p><strong>Methods: </strong>A retrospective study was performed collecting preinterventional and postinterventional DUS and ICG NIR fluorescence imaging measurements from LEAD patients undergoing revascularization. The correlation between the preinterventional and postinterventional perfusion parameters, described as the delta (Δ) ACC<sub>max</sub> and ΔICG NIR fluorescence parameters, were analyzed. Improvements in perfusion parameters were compared to clinical outcomes, defined as improvement in pain-free walking distance, freedom from rest pain, or tendency toward wound and ulcer healing.</p><p><strong>Results: </strong>A total of 38 patients (42 limbs) were included. ACC<sub>max</sub> and ICG NIR fluorescence perfusion parameters improved significantly after revascularization (p<0.001). Patients with a poor clinical outcome had a significantly lower improvement of both parameters after revascularization (p<0.001-0.016). Lack of correlation was found between the delta of ACC<sub>max</sub> and ICG NIR fluorescence imaging. Multiple non-congruent improvements of macrovascular parameters (ACC<sub>max</sub>) and perfusion (ICG NIR fluorescence) were seen within patients. However, for all patients with a successful clinical outcome, at least one parameter improved.</p><p><strong>Conclusion: </strong>Combining ACC<sub>max</sub> and ICG NIR fluorescence imaging revealed improvement in at least one parameter within all patients with a successful clinical outcome. This study highlights the potential of assessing both the macrovascular state and tissue perfusion following lower extremity revascularization, as both appear to reflect different aspects of vascularization.Clinical ImpactNumerous techniques have been developed to assess tissue perfusion to predict clinical outcomes following revascularization in patients with peripheral artery disease. However, none are widely implemented in clinical practice. This study emphasized the importance of employing multiple modalities from different perspectives for more accurate prediction. By focusing on both the macrovascular state and tissue perfusion, clinicians can better guide themselves in their treatment strategies.</p>","PeriodicalId":50210,"journal":{"name":"Journal of Endovascular Therapy","volume":" ","pages":"659-668"},"PeriodicalIF":1.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12972090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142134311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Endovascular Therapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1